According to a study released today by UCLA’s Jonsson Comprehensive Cancer Center, the overwhelming majority of patients with high-grade non-muscle invasive bladder cancer do not receive the recommended treatment and surveillance, leaving them at higher risk for bladder cancer recurrence, progression, and death.
The UCLA study examined the records of more than 4,500 bladder cancer patients from across the country. These patients had high grade, relatively aggressive disease that had not invaded the muscle wall of the bladder. Of the patients studied, only 1 out of 4,500 received treatment that met all of the recommended guidelines for care as issued by the American Urological Association and National Comprehensive Cancer Network.
The Bladder Cancer Advocacy Network (BCAN), the first national organization dedicated to advancing bladder cancer research and public awareness, is not surprised by the study results, said Lawrence Rzepka, BCAN Executive Director. “However, we continue to be disappointed by the low quality of care and attention many bladder cancer patients are receiving.”
Read more about the study... http://www.sciencedaily.com/releases/2011/07/110711081417.htm